Switching to AROMASIN showed no significant survival benefit over tamoxifen therapy.

What is AROMASIN? Learn about AROMASIN, a treatment for early breast cancer. Find out

AROMASIN and tamoxifen A clinical study showed that switching to AROMASIN after 2 to 3 years of tamoxifen reduced the risk of breast cancer recurrence versus staying on tamoxifen for 5 years. Learn more

FREE 30-day trial offer Want a FREE 30-day trial of AROMASIN and free info on staying healthy from AROMASIN PETALS? Get voucher

Contact Us   Terms of Use   Privacy Policy   Site Map   Unsubscribe
For Health Care Professionals

Copyright © 2008 Pfizer Inc. All rights reserved.

The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.

The health information herein is provided for educational purposes only and is not intended to replace discussions with a health care provider. All decisions regarding patient care must be made with a health care provider, considering the unique characteristics of the patient.